Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.43 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP8 | P22894 | 1/20 | 0.40 |
| ▸ | MMP14 | P50281 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4342743 | 0.98 | ITGB1 (0.43) | MMP1ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL4344292 | 0.95 | NPC1 (0.42) | MMP1ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL4344819 | 0.90 | MMP1 (0.43) | MMP1ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL4335828 | 0.88 | MME (0.43) | MMP1ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL1152902 | 0.87 | MMP1 (0.44) | MMP1ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL1153598 | 0.87 | MMP1 (0.44) | MMP1ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL1153888 | 0.87 | MMP1 (0.44) | MMP1ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL1153623 | 0.87 | MMP1 (0.44) | MMP1ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL1153676 | 0.86 | MMP1 (0.44) | MMP1ITGB1ITGA4NPC1RAB9A | |
| SCHEMBL1153931 | 0.86 | MMP1 (0.44) | MMP1ITGB1ITGA4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-05-03 | — | — | US | disclosed |
| EP-1698616-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | CCNL2, ARL1, ACSL3 | MMP1 4407/4885ITGB1 1633/4885ITGA4 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.